Sooner May Still Be Too Late: Kidney Biopsies in SLE #ACR25 kicked off with Plenary Session by Michelle Petri (Abstract 0772: Redefining When to Biopsy the Kidney in Patients with SLE. As part of a collaboration with the Accelerating Medicines Partnership, Petri and colleagues https://t.co/bU09vpcDew

#2682 In a randomised trial of 320 RA patients, the recombinant zoster vaccine (RZV) was safe and did not trigger disease flares. But methotrexate use and older age significantly blunted antibody responses ➡️key factors to consider for vaccine strategies in RA. @RheumNow #ACR25

Abstract 2697: Compared to MMF, tacrolimus showed - similar SRR by week 96 (58.5% vs. 69.2%, OR 0.62; 95% CI 0.29-1.29) - similar time to renal AE/deaths (HR 0.70; 95% CI 0.37-1.35) - serious AEs less frequent (12.3% vs. 30.8%) @RheumNow #ACR25 https://t.co/o3LtgOp7St

• https://x.com/AkhilSoodMD/status/1983581595979117052/photo/1

Abstract 2696: Phase 1/2 study of rapidly engineered CD19 CAR T showed: - rapid depletion of CD19 B cells w/ recovery by Day 90 - Days 180 and 360: returning B cells largely naive (CD27-IgD+) - Interferon expression ↓ after CAR T treatment @RheumNow #ACR25 https://t.co/FzdFbqWwtE

• https://x.com/AkhilSoodMD/status/1983579079237386732/photo/1
• https://x.com/AkhilSoodMD/status/1983579079237386732/photo/1

#ACR25 Abstr#2697 H2H RCT of Tacrolimus + GC vs MMF + GC in #lupus Nephritis in Asia for Induction-Maintenance showed similar efficacy. Different side effects: AKI more in TAC, low WCC & infections in MMF. Informative for services with no access to biologics/Voclosporin @RheumNow https://t.co/V4uWhuqjjW

• https://x.com/Yuz6Yusof/status/1983578834315157825/photo/1

#2658 In >870k adults with T2DM or obesity, GLP-1 receptor agonists showed no increase in autoimmune or inflammatory disease risk, and were instead linked to lower mortality, heart failure, stroke and dementia. Excellent real-world safety signals. @RheumNow #ACR25

Abst 2694: Post-hoc analysis of Phase 2 PAISLEY SLE trial examined impact of deucravacitinib on renal dysfunction 🔹 Plasma proteins a/w ↑ BILAG renal score and ↓ UPCR --> reduced by WK 32 🔹 Biomarkers inversely related to eGFR were reduced with deucra vs PBO @RheumNow #ACR25 https://t.co/6CvmQ9lCfS

• https://x.com/AkhilSoodMD/status/1983576311118389425/photo/1
• https://x.com/AkhilSoodMD/status/1983576311118389425/photo/1

Lots of interest in MRI for GCA diagnosis... but what about monitoring? Case series of 14 pts: MRI identified relapse prior to symptoms or inflammatory markers in 2 cases, including those on TCZ, which hides them More available in US context, noninvasive, & more structures https://t.co/pnrI9SEpll

• https://x.com/EBRheum/status/1983575532861083696/photo/1

This prospective study from Brazil evaluated the effect of RHZ vax in SSc pts SSc pts had ⬆️rates of seroconversion mean titers ⬆️ from BL Local rxs ⬇️ in SSc pts Systemic rxns comparable among the 2 grps interesting data. longterm studies still needed #ACR25 @RheumNow Abs2653 https://t.co/wJqpPrAHKG

• https://x.com/RHEUMarampa/status/1983559370366664781/photo/1
• https://x.com/RHEUMarampa/status/1983559370366664781/photo/1
• https://x.com/RHEUMarampa/status/1983559370366664781/photo/1

Thank you @drdavidliew & @DrLauraCoates ❤️ for highlighting our work. Super-responders (some were IS-Free) do exist with rituximab in #SLE Abstr#1525 @RheumNow https://t.co/S4mMAYInfT

• https://twitter.com/drdavidliew/status/1983555936657854811

Year in Preview SLE: 52% subtherapeutic on weight based HCQ dosing Precision prescribing needed, more so for CKD @RheumNow #ACR25 Abstract 1722 https://t.co/8WqorQ1xJx

• https://x.com/JihaRheum/status/1983555467344310342/photo/1

Hydroxychloroquine in SLE is all about the sweet spot. Not too hot with retinopathy, not too cold with flares, just right by the levels. Yet drug concentrations and TDM are not commonplace in many places - time for change Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/oB3ecfSQQc

• https://x.com/drdavidliew/status/1983555247269404896/photo/1

ACR25 coming to a close with Clinical Year in Preview For PsA, can biologics prevent damage? If so, which one? Difficult to answer often b/c confounding by indication. NLP-informed propensity matching beyond demographics for clinical factors like BSA @RheumNow #ACR25 A#2689 https://t.co/jjpb0kTo34

• https://x.com/JihaRheum/status/1983551740202095038/photo/1

In a U.S. axSpA cohort (n=4,799), women had a 24% higher adjusted risk of TNFi discontinuation vs men especially under age 65. No sex differences seen for IL-17i or JAKi, though sample sizes were small. Highlights need for sex-informed treatment strategies. Abstract#2634 https://t.co/58Dw3nFCsf

• https://x.com/synovialjoints/status/1983549391203119443/photo/1